BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing artificial intelligence, or AI, approaches to develop transformative medicines in neuroscience and immuno-oncology.

Innovating Medicine by Leveraging Artificial Intelligence

We are focused on utilizing cutting-edge technology and innovative research to develop high-value therapeutics aimed at transforming patients’ lives. BioXcel Therapeutics employs a unique AI platform in an effort to reduce therapeutic development costs and potentially accelerate timelines while aiming to increase the possibility of success. Our approach leverages existing approved drugs and/or clinically evaluated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. We believe that this differentiated approach has the potential to reduce the expense and time associated with drug development in diseases with substantial unmet medical needs.

Our Differentiated Approach

Therapeutic Area Focus

Targeting neuroscience disorders and immuno-oncology with significant unmet medical need and large market opportunity

Drug Re-Innovation

The proprietary drug development approach aims to leverage existing approved drugs and/or clinically evaluated product candidates

Higher Probability of Success

Developing first-in-class drug candidates while aiming for a higher probability of clinical and regulatory success

Therapeutic Benefit

Potential to provide clinical benefit to patients in need